IQVIA Holdings Inc(IQV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 31.88 | EPS (ttm) | 8.06 | Insider Own | 1% | Shs Outstand | 164.6M | Perf Week | -0.53% |
| Market Cap | 42.30B | Forward P/E | 17.82 | EPS next Y | 11.21% | Insider Trans | -6.89% | Shs Float | 163.0M | Perf Month | 6.19% |
| Enterprise Value | 56.59B | PEG | 1.67 | EPS next Q | 3.27 | Inst Own | 102.22% | Short Float | 2.61% | Perf Quarter | 37.98% |
| Income | 1.38B | P/S | 2.49 | EPS this Y | 8.79% | Inst Trans | -1.27% | Short Ratio | 2.94 | Perf Half Y | 50.34% |
| Sales | 16.99B | P/B | 6.85 | EPS next 5Y | 10.65% | ROA | 4.7% | Short Interest | 4.25M | Perf YTD | 14.01% |
| Book/sh | 37.49 | P/C | 20.34 | EPS past 3/5Y | 11.05% 40.52% | ROE | 23.01% | 52W High | -5.45% ($271.80) | Perf Year | 35.51% |
| Cash/sh | 12.64 | P/FCF | 19.37 | Sales past 3/5Y | 4.18% 7.5% | ROIC | 6.83% | 52W Low | 66.33% ($154.50) | Perf 3Y | 20.35% |
| Dividend Est. | - | EV/EBITDA | 15.96 | EPS Y/Y TTM | 16.68% | Gross Margin | 26.02% | Volatility(W/M) | 2.9% 2.89% | Perf 5Y | -1.65% |
| Dividend TTM | - | EV/Sales | 3.33 | Sales Y/Y TTM | 8.22% | Oper. Margin | 13.9% | ATR (14) | 7.54 | Perf 10Y | 233.44% |
| Dividend Ex-Date | - | Quick Ratio | 0.71 | EPS Q/Q | -0.36% | Profit Margin | 8.09% | RSI (14) | 56.8 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.71 | Sales Q/Q | 8.84% | SMA20 | 0.57% ($255.52) | Beta | 1.18 | Target Price | $276.76 |
| Payout | - | Debt/Eq | 2.63 | Earnings | 2026/7/28 | SMA50 | 10.4% ($232.77) | Rel Volume | 0.75 | Prev Close | $259.21 |
| Employees | 93000 | LT Debt/Eq | 2.26 | EPS/Sales Surpr. | 3.88% 1.53% | SMA200 | 27.03% ($202.3) | Avg Volume(3M) | 1.45M | Price | $256.98 |
| IPO | 2013/5/9 | Option/Short | Yes/Yes | Trades | 17269 | Volume | 1,090,226 | Change | -0.86% |
Company
IQV is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A comprehensive healthcare services company that provides global clinical trial Contract Research Organization (CRO), healthcare data, analytics, and commercialization solutions. Headquartered in Durham, North Carolina, the company combines clinical trial services with global prescription and medical data analytics through its unique business model, ranking among the top in market capitalization within the global CRO and healthcare data analytics group.
Over the past 1 year, on the higher side
5% below its 1-year high.
IQV has weak earning power
13.9% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.8% this year.
Tap to view numbers
The price looks about right
Trading at 31.9 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +20.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 102.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EKG 0.08%
LGHT 0.05%
HEAL 0.05%
DIVE 0.05%
BBH 0.04%It ranks #4 in the industry
Based on market cap of $42B.
IQV $42B PER 31.9
TMO $224B PER 32.6
DHR $144B PER 36.4
NTRA $48B PER -
FAQ
What kind of company is IQV?
IQV belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of IQV?
The market cap of IQV is approximately $42.3B, ranking 368 within its sector.
What is the P/E ratio of IQV?
IQV has a P/E ratio of approximately 31.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for IQV?
IQV has recorded a 52-week high of $271.80 and a low of $154.50.
